Feb 23, 2014 by Dan Carroll3 Under-the-Radar Biotech Stocks You Need to Watch in 2014Nektar Therapeutics, Omeros, and Spectrum Pharmaceuticals all face off with regulators in key decision dates for their developmental drugs later this year
Feb 21, 2014 by Dan CarrollBoeing Stock Drop Drags Down the DowThe Dow Jones falls below breakeven after an up-and-down day, while Biogen Idec's shares jump.
Feb 20, 2014 by Dan CarrollWal-Mart's Earnings Slump Can't Stop the Dow's 100-Point BounceVerizon soars after the FCC waves the white flag on a recent court ruling over net neutrality.
Feb 19, 2014 by Dan CarrollChevron's Stock Bubbles Higher as the Dow Sheds Early GainsMerck falls to lead a cadre of Dow losers on an up-and-down market day.
Feb 18, 2014 by Dan CarrollCoca-Cola's Stock Fizzles, Dow Wobbles on a Muted Day for InvestorsJohnson & Johnson's stock falls after blood thinner Xarelto is denied expanded uses.
Feb 17, 2014 by Dan CarrollCan These 2 Health Care Giants Overcome Big Pharma's Alzheimer's Struggles?Alzheimer's has been one of the trickiest diseases for big pharma to develop drugs for lately, but Merck and AstraZeneca are pushing into late-stage trials with two high-potential drugs.
Feb 14, 2014 by Dan CarrollObamacare's Rebound Helps UnitedHealth Lead the Dow's Triple-Digit JumpObamacare sign-ups surge in January, pushing UnitedHealth and other insurance stocks up big today as part of the market's rally.
Feb 13, 2014 by Dan CarrollCisco's Earnings Plunge Weighs Down the Dow's ComebackOutside the Dow, Time Warner and Comcast make history by announcing a $45 billion merger.
Feb 13, 2014 by Dan Carroll3 Next-Generation Trends in Medical Tech You Need to KnowFrom new takes on old technologies to cutting-edge innovations such as robotic surgery and bioprinting, these trends are revolutionizing the future of med tech.
Feb 12, 2014 by Dan CarrollThe Dow Drops Behind Procter & Gamble's Emerging-Market DisappointmentProcter & Gamble cuts core earnings and sales growth expectations, but investors shouldn't be too concerned over this consumer giant's direction.
Feb 11, 2014 by Dan CarrollMerck Leads Health Care's Bounce as the Dow Jumps Almost 200 PointsJohnson & Johnson and Merck rank among the Dow's leaders on a great day for investors across the markets.
Feb 10, 2014 by Dan CarrollUnitedHealth Noses Down to Lead the Dow's DipMcDonald's takes a U.S. same-store sales beating in January despite strong global growth.
Feb 7, 2014 by Dan CarrollBoeing Jets Higher as the Dow Closes the Week With a Triple-Digit ClimbIBM rises on reports it may sell its semiconductor business, while America overlooks a weak jobs report for January
Feb 6, 2014 by Dan CarrollIs Boston Scientific's Turnaround the Start of a Health Care Surge?In the wake of Boston Scientific's comeback from slumping revenues, key device leaders such as St. Jude Medical and Medtronic have plenty of room to run for investors.
Feb 6, 2014 by Dan CarrollDisney Heats Up the Dow Behind a Star-Studded First-Quarter PerformanceDisney's big success at the box office propels its standout earnings report, while Coca-Cola spices up the markets as it pushes into the do-it-yourself beverage market.
Feb 5, 2014 by Dan Carroll3M's Buyback Bounce Keeps the Dow's Head Above WaterMerck lags after reporting lackluster fourth-quarter earnings on a day in which blue-chip stocks struggle to stay afloat.
Feb 4, 2014 by Dan CarrollDuPont Soars to Lead the Dow's ComebackAfter yesterday's market bloodbath, DuPont and Merck are among a handful of high-performing stocks on the Dow Jones today.
Feb 3, 2014 by Dan CarrollWhy Today's Dow Plunge Shouldn't Shake Your Investing ConfidenceThe VIX soars behind a poor result from the ISM's PMI, but a one-month dive in American manufacturing isn't reason to panic just yet.
Feb 1, 2014 by Dan CarrollJohnson & Johnson's 3 Fastest-Growing BusinessesJohnson & Johnson's made the most of the market's rally over the past year, but three divisions of this broad health-care company have posted up stellar growth.
Jan 31, 2014 by Dan Carroll3 Things to Watch in Merck's Upcoming EarningsMerck has struggled with the patent cliff's hit on its sales lately, but can this top pharma stock bounce back with earnings on tap?
